2.2 GIPR agonism serves to reduce GLP-1R mediated GI AEs in the clinic Treatment with GLP-1R agonists can drive nausea, diarrhea, vomiting, and constipation, which often results in discontinuation of treatment (6-10% of patients) or reduction in dose (~15% of patients) (63)
In clinical trials, the medication was stored under standard refrigeration conditions similar to other injectable peptide medications
Patients should not change their dose or treatment schedule without medical guidance
McTiernan, N., Kjoss, I., & Arnesen, T
It's assuming they're functionally equivalent because both activate melanocortin pathways
It directly inhibits tyrosinase, the enzyme responsible for converting tyrosine into melanin, by binding to copper ions at the enzymes active site